Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Travoprost/Timolol Fixed Combination vs Latanoprost + Timolol in Glaucoma
NCT00293787Phase 3
Key facts
- Status
- Completed
- Start
- Jun 2004
- Primary completion
- Aug 2005
- Sponsor
- Alcon Inc.
- Modality
- Small Molecules
- Drugs
- travoprost + timolol
- Conditions
- open-angle glaucoma (OAG)ocular hypertension
01
Overview
Phase 3, randomised, double-blind trial of travoprost + timolol in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Alcon Inc. Primary endpoint: Mean intraocular pressure change from baseline at 3 months. Started Jun 2004; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Travoprost/Timolol
Travoprost 0.004%/Timolol 0.5% AM + Vehicle PM
Latanoprost + Timolol
Timolol 0.5% AM + Latanoprost PM
03
Who it enrols
Adult patients with open-angle glaucoma or ocular hypertension and mean IOP < 18 mmHg at screening.
04
Endpoints
Primary
Mean intraocular pressure change from baseline
Beyond the preview
Go deeper on NCT00293787.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293787.